Concomitant mutation and amplification could indicate oncogene addiction, but since targeted therapy for KIT-mutated AM and MM is generally not licensed and not available for broad use, it is challenging to obtain samples to validate our study. This evidence concerns the gene KIT and Miyoshi myopathy.